Pre-clinical assessment of JAK inhibitors to ameliorate cytokine storms in Down syndrome

Sullivan, Kelly D

Summary​

There is an urgent need for therapeutic interventions to treat the symptoms of SARS-CoV-2/COVID-19 associated with severe outcomes; including cytokine release syndrome which is implicated in acute respiratory distress syndrome, heart failure, and death. The work outlined in this proposal will test the ability of FDA- approved JAK inhibitors to rescue cytokine production and multi-tissue inflammation in a mouse model of non- infectious immune hypersensitivity. This work will provide pre-clinical data in support of ongoing clinical trials aimed at treating harmful immune responses in COVID-19.

Down Syndrome Publications​